A San Francisco investment firm has built a large stake in New Haven-based Arvinas Inc., and has been pressing for sweeping changes, including a refocus of the bioscience company’s drug pipeline and significant cost reductions.
The firm, Logos Global Management, recently disclosed through U.S. Securities and Exchange Commission filings that it has amassed an 8.6% stake in Arvinas, one of Connecticut’s most prominent life sciences companies. In correspondence with Arvinas’ board, Logos has called for a strategic overhaul, arguing the company must narrow its research priorities and cut expenses to improve shareholder returns.
Amid the pressure campaign, Arvinas announced in July that its longtime CEO John Houston will retire, with a search for his successor now underway.
In a statement to Hartford Business Journal, Arvinas said it “values the perspectives of its shareholders and welcomes feedback as its Board of Directors considers all ideas that will support the shared goal of maximizing shareholder value. In recent months, the Board and management team have taken decisive actions to strengthen the Company’s position while we make progress across our pipeline.”
Arvinas also said Houston’s decision to retire was not linked to any shareholder pressure.
John Houston
“As with any public company, succession planning is a priority for our Board of Directors, and John had been talking to the Board about the potential timing of his retirement for well over a year,” the company said.
Eventful year
Arvinas, founded in 2013, is known for its work in developing protein degradation therapies designed to remove disease-causing proteins from the body. It’s a field that has drawn strong interest from global pharmaceutical companies.
In 2021, for example, Arvinas signed a $2.4 billion deal with Pfizer to jointly develop vepdegestrant, an investigational breast cancer treatment.
On its website, the company lists about 10 drug discovery programs in its oncology and neuroscience pipelines.
But Arvinas has faced challenges over the past year, announcing in May plans to lay off 131 employees, or a third of its workforce, as it discontinued two phase 3 trials with Pfizer related to its breast cancer treatment development plan.
A year ago, Arvinas also disclosed it was scrapping plans to occupy 163,784 square feet of space in a new life sciences building in New Haven, at 101 College St. It agreed to pay the landlord a $41.5 million lease termination fee.
Despite reporting a larger second-quarter net loss in 2025 compared to a year earlier, Arvinas did reduce its operating expenses by $31.1 million during the three-month period.
At the end of June, Arvinas reported $861.2 million in cash, cash equivalents and marketable securities, which it said was sufficient to fund planned operating expenses into the second half of 2028.
Its stock price closed Tuesday at $7.54, well below its 52-week high price of $29.61.
‘Constructive dialogue’
Logos Global Management is a subsidiary of Logos Capital, an investor in bioscience companies. Logos lists about 100 portfolio companies on its website.
In June, the company disclosed it took a 6.4% stake in Arvinas, purchasing 4.8 million shares of stock. In an SEC filing, Logos said it sent an email on June 10 to Arvinas’ board members “recommending a strategic reset of the company's direction and structure.”
The email urged the board to consider a special distribution to stockholders, refrain from further investment in the early-stage pipeline, and adopt a leaner operating model focused on preserving cash.
“In addition, we believe that the company should not move forward independently on its lead asset absent the involvement of a committed strategic partner,” the email said.
In August, Logos revealed that it increased its stake in Arvinas to 8.6%, with control over 6.3 million shares. The investment firm said it sent another letter to Arvinas’ management and board on Aug.7 that “expressed appreciation for the constructive dialogue to date with senior leadership and the board, while recommending that the company adopt an urgent strategic reset to restore shareholder confidence and preserve value.”
The letter urged the board to return $700 million of capital to stockholders, substantially reduce operating expenses, “allow the company's valuation to rebase around its core science,” execute a 1-for-5 reverse stock split to facilitate institutional re-engagement, and “rebuild the company's credibility through disciplined capital allocation and business development.”
